Home Biosimilar Antibodies Immunology & Inflammation CD markers Indatuximab (Anti-Syndecan-1 / CD138)
For research use only. Not for use in humans.

Indatuximab (Anti-Syndecan-1 / CD138)

Synonyms: T-cell receptor， T-cell antigen receptor

Indatuximab (Anti-Syndecan-1/CD138) is an antibody against Syndecan-1. MW : 145.5 KD

Indatuximab (Anti-Syndecan-1 / CD138)

Quality Control

Batch: A234201 Purity: 99% Protein concentration: 10.1mg/ml Endotoxin Level: ＜1EU/mg
99

Specificity

Name Citation CD38 CD45 CD39 CD88 CD73 Others
RBN013209 0
MK-0159 0
CD38 inhibitor 1 (compound 78c) 7
AB680 1
NQ301 1 TXA2 receptor
SodiuM Metatungstate 3
PMX-53 3
LY-3475070 2
Expand to Check More
1. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation. 2. "✔" indicates inhibitory effect, but without specific value.

Mechanism of Action

Description
Indatuximab (Anti-Syndecan-1/CD138) is an antibody against Syndecan-1. MW : 145.5 KD

Product Details

Molecular Weight 145.5 kDa
Isotype Human IgG4SP
Source CHO
Purification AKTA
Sterility 0.2 μM filtered
Formulation 100 mM Pro-Ac, 20mM Arg, pH5.0
Storage
(From the date of receipt)		 Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles.

Comparison of Clones for

*Literature analysis of various clone (for this target) products available on the market shows that Selleck's selected clones are more frequently applied. (data until September 2024)

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT03196414 RECRUITING Multiple Myeloma The First Affiliated Hospital of Soochow University 2016-09 PHASE1; PHASE2
NCT03672318 ACTIVE_NOT_RECRUITING Drug: CAR138 T Cells Multiple Myeloma; Immune System Diseases UNC Lineberger Comprehensive Cancer Center 2019-01-14 PHASE1
NCT03778346 UNKNOWN RRMM The Sixth Affiliated Hospital of Wenzhou Medical University 2018-11-15 PHASE1
NCT03689101 COMPLETED Infertility Reproductive & Genetic Hospital of CITIC-Xiangya 2016-03-21

(data from https://clinicaltrials.gov, updated on 2019-05-02)

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.